Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: February 2014 (Event date: February 6, 2014)
Context: The filing reports a corporate event regarding the advancement of the company's clinical development program.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is an event-driven report and does not contain financial statements or performance metrics.
Material Changes
Clinical Development Update: On February 6, 2014, the company submitted a Phase II study protocol for its investigational drug, CF102. The study is designed to treat patients with advanced liver cancer.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the submission of the Phase II protocol. No specific financial guidance, outlook, or risk factors are explicitly detailed within the text of this specific filing form.
Investor Verification Checklist
- Verify the full details of the Phase II study protocol for CF102 in the attached press release (Exhibit 99.1).
- Confirm the regulatory status and timeline for the initiation of the advanced liver cancer trial.
- Review the company's most recent Form 20-F or quarterly reports for current financial liquidity and cash runway, as this filing contains no financial data.